Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBIg and Peginterferon for Chronic Hepatitis B
NCT03575208Phase 2Withdrawn
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Feb 2019
- Primary completion
- Mar 2022
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of hepatitis B immune globulin in Chronic Hepatitis B (CHB), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Planned start Feb 2019; status: withdrawn.
02
Drugs
hepatitis B immune globulin
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03575208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03575208.